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Claire Pichereau,1 Kristell Desseaux,2 Anne Janin,3,4,5 Catherine Scieux,3,6
Regis Peffault de Latour,1,3 Alienor Xhaard,1,3 Marie Robin,1 Patricia Ribaud,1,3
Felix Agbalika,3,6 Sylvie Chevret,2,3,7 Gerard Socie1,3,4The most frequent manifestation of human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoi-
etic stem cell transplantation (HSCT) is febrile rash, raising the question of its relationship with graft-versus-
host disease (GVHD). In this retrospective analysis of 365 patients who underwent allogeneic HSCT, HHV-6
reactivation was significantly associated with cord blood transplantation (hazard ratio [HR], 3.20; P\.0001)
and the use of unrelated donors (HR, 2.02; P 5 .008). On multivariate analysis, previous GVHD was a pre-
dictive factor for HHV-6 reactivation (HR, 1.80; P 5 .01), and previous HHV-6 reactivation was a predictive
factor for acute GVHD (HR, 1.66; P5 .03). Nineteen patients with no pathological evidence of GVHD later
developed severe clinical GVHD (grade III-IV), suggesting the role of HHV-6 as a trigger for severe GVHD.
Furthermore, 17 patients without histopathological GVHD demonstrated a significant lymphoid infiltrate
suggesting ‘‘pure’’ HHV-6–related manifestations, and these patients could have been spared steroid therapy.
Biol Blood Marrow Transplant 18: 141-144 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Transplantation, GvHD, Human, GvHD diagnosisINTRODUCTION (HSCT). The pathogenicity of the virus is unclear, butHuman herpesvirus 6 (HHV-6), a member of the
betaHerpesviridae family, is the causative agent of exan-
thema subitum, a childhood disease characterized by fe-
ver and skin rash. Almost 90% of the population is
infected within the first 18 months of life. Similar to
the other human herpesviruses, HHV-6 remains latent
after primary infection but can be reactivated in immu-
nocompromised patients. Reactivation occurs in 38%-
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6/j.bbmt.2011.07.018it has been associated with delayed platelet and granulo-
cyte engraftment [1,2], myelosuppression [3], pneumo-
nitis [4], encephalitis [5-7], and febrile skin rash [8].
HHV-6–related manifestations and acute graft-
versus-host disease (aGVHD) symptoms share com-
mon clinical features and often have been associated
with one another [9,10].WhetherHHV-6 reactivation
is a cause or a consequence of aGVHD remains un-
clear, however. It also could be considered a differential
diagnosis of aGVHD [11].
We conducted a retrospective study of 414 consec-
utive patients who underwent allogeneic HSCT at
Saint Louis Hospital, Paris, between 2004 and 2007,
365 of whom were tested for HHV-6 at least once in
the early post-HSCT period.
PATIENTS AND METHODS
Patient Characteristics
Of the 414 consecutive patients who underwent
allogeneic HSCT at Saint Louis Hospital between
January 2004 and December 2007, 365 patients were
tested for HHV-6. Clinical features prompting testing
for the virus were febrile skin rash, diarrhea or hepatic
perturbations, neurologic disorders, and pneumonia.
Viral assays were performed over a median period of
107 days (range, 43-245 days). The median number
of viral assays per patient was 7 (range, 3-15). Assays141
Table 1. Characteristics of Patients (n 5 365)
Sex, n (%)
Male 224 (61.4)
Female 141 (38.4)
Age, years, median (range) 31 (16-45)
Diagnosis, n (%)
Malignant disorders 300 (82.2)
Acute leukemia 178 (48.8)
Myelodysplasia 30 (8.2)
Chronic myelogenous leukemia 21 (5.8)
Lymphoma 33 (9)
Multiple myeloma 15 (4.1)
Myelofibrosis 12 (3.3)
Other 11 (3)
Nonmalignant disorders 65 (17.8)
Aplastic anemia 43 (11.8)
Sickle cell disease 19 (5.2)
Thalassemia 3 (0.8)
Disease status, n (%)
Early* 136 (46.9)
Advanced† 154 (53.1)
Donor, n (%)
Related donor 180 (49.3)
Unrelated donor 185 (50.7)
Donor HLA match, n (%)
Identical sibling 175 (48)
Matched other relative 1 (0.3)
Matched unrelated 96 (26.3)
Mismatched relative 4 (1.1)
Mismatched unrelated 80 (21.9)
Unrelated not otherwise specified 9 (2.5)
Conditioning regimen, n (%)
Myeloablative 225 (61.6)
Reduced intensity 140 (38.4)
Stem cell source, n (%)
Bone marrow 154 (42.2)
Peripheral blood 152 (41.6)
Cord blood 59 (16.2)
CR indicates complete remission; PR, partial remission.
*CR1, PR1, or chronic phase.
†CR2, CR3, PR2, no CR, accelerated, stable, progression, failure, or
relapse.
142 Biol Blood Marrow Transplant 18:141-155, 2012C. Pichereau et al.were performed every 8 days on average (range, 4-20
days). There were no significant differences between
the patients who were tested and those who were not
tested, except for history of aGVHD (65.5% versus
38.8%; P5 .0005). Patient characteristics are summa-
rized in Table 1. Prophylaxis for aGVHD consisted of
either a combination of cyclosporine and a short
course of methotrexate (myeloablative conditioning),
or a combination of cyclosporine and mycophenolate
mofetil (reduced-intensity conditioning), or cyclo-
sporine alone in patients receiving cord blood trans-
plants. The first-line treatment for aGVHD was i.v.
methylprednisolone 1-2 mg/kg/day.Real-Time Quantitative Polymerase Chain
Reaction
DNA was extracted from 200 mL of EDTA whole
blood using theMagNAPure LCExtractor withDNA
Isolation Kit I (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instruc-
tions. HHV-6 real-time quantitative polymerase chain
reaction (RT-qPCR) analysis amplifying a DNA poly-
merase U38 gene fragment was performed with an ABIPrism 7500 analyzer using TaqMan technology
(Applied Biosystems, Applied-Biosystems, Courta-
boeuf, France), as described previously [12].
Histopathological Analysis
Skin or gut biopsy specimens were collected at the
timeofonsetof aGVHDbefore initiationof steroid ther-
apy. For the purpose of this study, all biopsy charts were
reviewed, and mononuclear cell infiltrate was scored
retrospectively. Otherwise, pathological grade was com-
puterized withoutmodification from the original report.
Definitions
AcuteGVHDwas defined and graded according to
Glucksberg’s criteria. Active HHV-6 reactivation was
defined as the detection of at least 100 copies of viral
DNA per mL of whole blood by RT-qPCR.
Statistical Analysis
Cumulative incidence was estimated using a com-
peting-risk approach. Predictive factors of increased
risk of reactivation or aGVHD were assessed using
cause-specificCox hazardmodels.The effects of reacti-
vation on further occurrence of aGVHD and vice versa
were tested by introducing a time-dependent variable.RESULTS AND DISCUSSION
Among 365 patients tested for HHV-6, 239 had
aGVHD (65.5%) and 100 experienced HHV-6 reacti-
vation (89 before day 120). Sixty-nine infected patients
developed aGVHD (64 before day 120 post trans-
plant). The occurrence of aGVHD was not signifi-
cantly different between the patients with HHV-6
reactivation and those without reactivation (69.0%
versus 64.2%; P5 .38), but those with HHV-6 reacti-
vation hadmore severe manifestations (ie, grade III-IV
aGVHD; P 5 .03). The median time of reactivation
was 28 days post-HSCT (range, 18-71 days) and 4
days after the first signs of aGVHD (range, -2 to 20
days). HHV-6 reactivation occurred in 56.3% of pa-
tients between 10 days before and 10 days after the oc-
currence of aGVHD (in 36 of the 64 cases before day
120). When HHV-6 reactivation occurred after the
development of aGVHD, the median time of onset
was 18 days (range, 6-71 days post HSCT) after the
start of treatment for GVHD. The cumulative inci-
dence of aGVHDwas 65.5% and that of HHV-6 reac-
tivation was 26.9%, using death before aGVHD/
HHV-6 reactivation as a competitive event.
In univariate analysis, there were significant associ-
ations between HHV-6 reactivation and the use of
cord blood as the stem cell source (56.2% versus
22.3%; P \ .0001) (Figure 1A), unrelated donor
(39.3% versus 15.7%; P \ .0001) (Figure 1B), and
age \45 years (30.7% versus 20.5%; P 5 .02), but
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Figure 1. A, Cumulative incidence of HHV-6 reactivation in patients
who underwent allogeneic HSCTwith unrelated cord blood or other
stem cell sources. B, Cumulative incidence of HHV-6 reactivation in pa-
tients who underwent allogeneic HSCTwith an unrelated donor or an
HLA-identical sibling donor.
Table 2. Predictive Factors for Increased Risk of HHV-6 Re-
activation or aGVHD before Day 120 in Multivariate Analysis
Variable HR 95% CI P Value
HHV-6 reactivation
Cord blood as a stem cell source 3.20 1.96-5.20 <.0001
Unrelated donor 2.02 1.20-3.39 .008
Previous GVHD 1.80 1.13-2.88 .01
aGVHD
Stem cell source other than cord blood 2.22 1.48-3.32 .0001
Unrelated donor 1.84 1.42-2.38 <.0001
Myeloablative conditioning 1.51 1.17-1.95 .002
Previous HHV-6 reactivation 1.66 1.07-2.59 .03
HR indicates hazard ratio; CI, confidence interval.
Biol Blood Marrow Transplant 18:141-155, 2012 143HHV-6 in Human GVHDnot between HHV-6 reactivation and the type of con-
ditioning regimen or disease status (all P. .20) (Table
S1; available online). HHV-6 reactivation occurred
with equal frequency in patients who received thymo-
globulin as a part of the conditioning regimen and
those who did not (27.8% and 28%, respectively).
Cord blood transplantation and unrelated donor, but
not age \45, remained significant predictive factors
for HHV-6 reactivation in multivariate analysis
(Table 2), with respective hazard ratios (HRs) of 3.20
(95% confidence interval [CI], 1.96-5.20; P\ .0001)
and 2.02 (95% CI, 1.20-3.39; P 5 .008). This finding
is consistent with previous reports [7,13-15] and can
be explained by the immature immune system incord blood grafts and the intense immunosuppressive
therapy after HSCT from an unrelated donor.
Furthermore, previous GVHD, considered a time-
dependent covariate in a multivariate Cox model, was
a predictive factor for HHV-6 reactivation (HR,
1.80; 95% CI, 1.13-2.88; P 5 .01). Using the same
method, multivariate analysis confirmed that graft
source other than cord blood (HR, 2.22; 95% CI,
1.48-3.32; P 5 .0001), unrelated donor (HR, 1.84;
95%CI, 1.42-2.38; P\ .0001), andmyeloablative con-
ditioning (HR, 1.51; 95% CI, 1.17-1.95; P 5 .002)
were predictive factors for aGVHD (Table 2). More-
over, previous HHV-6 reactivation, considered
a time-dependent covariate, was also a predictive factor
for aGVHD (HR, 1.66; 95% CI, 1.07-2.59; P 5 .03).
These results confirm the positive association be-
tween aGVHD and HHV-6 reactivation, but do not
provide information on their temporal relationship.
HHV-6 seems to trigger aGVHD as frequently as it is
induced by aGVHD.The immunomodulatory proper-
ties of HHV-6 are complex. On one hand, HHV-6 has
cytopathic effects onCD4T cells [16], reduces the pro-
duction of interleukin-2 and cellular proliferation in in-
fectedT cells [17], and alters the expression of theT cell
receptor complex secondary to down-regulation of
CD3 T cells [18]. On the other hand, HLA class I and
II seem to be up-regulated after HHV-6 infection
[19], which triggers donor cytotoxic T cells. Finally,
HHV-6 infectiondramatically alters the releaseof cyto-
kines and chemokines, with increased levels of inflam-
matory cytokines, such as interleukin-1b and tumor
necrosis factor a [20]. The virus also expresses chemo-
kines and chemokine receptor homologues that could
participate in the recruitment of antigen-presenting
cells [21]. Finally, immune deficiency associated with
aGVHD and/or its treatment favors HHV-6 reactiva-
tion, as described with other viruses [22].
Tissue biopsy analysis results were available for
64 of the 100 HHV-6–infected patients (32 skin
specimens and 32 gut specimens). There were no sig-
nificant differences between patients who underwent
biopsy and those who did not, except for the incidence
of aGVHD (75% versus 50%; P5 .01). The combina-
tion of histopathological data and clinical observations
144 Biol Blood Marrow Transplant 18:141-155, 2012C. Pichereau et al.identified a group of 19 patients who had no or mild
histopathological GVHD (grade 0 or I) but subse-
quently developed severe clinical GVHD (grade
II-IV). HHV-6 reactivation occurred simultaneously
with or before the onset of aGVHD in the majority
of cases, and GVHD was resistant to steroids in
11 cases, suggesting the role of HHV-6 as a trigger
for severe aGVHD. These data confirm results of
Appleton et al. [23] and Wang et al. [9], who reported
a positive correlation between GVHD severity and the
presence of HHV-6 in skin or rectum biopsy speci-
mens and blood samples, respectively. Another subset
of infected patients (17 of 64, 26.6%) was of particular
interest because of the presence of an important lym-
phoid infiltrate in skin biopsy specimens, contrasting
with the absence of pathological evidence of aGVHD.
HHV-6 detection by RT-qPCR on biopsy could not
be studied, because no fresh or frozen tissue was
available. These data raise the possibility of ‘‘pure’’
HHV-6–related manifestations after allogeneic
HSCT, because no other viral reactivation (in parti-
cular, no cytomegalovirus reactivation) occurred
simultaneously. Yoshikawa et al. [11] suggested the ex-
istence of a viral exanthema caused by active HHV-6
infection early after HSCT, but failed to differentiate
it from the cutaneous manifestations of aGVHD, be-
cause no correlations were made among histopatho-
logical, virological, and clinical data.
In conclusion, in this, the largest study reported to
date, we confirm the association between HHV-6 and
aGVHD and suggest the role of HHV-6 as a trigger
for severemanifestationsofGVHD.Our results also sug-
gest that ‘‘pure’’ HHV-6–related manifestations can be
viewed as a differential diagnosis of aGVHD in a subset
of patients who could then be spared steroid treatment.
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